

Supplementary Figure 1. Treatment schema.

			Cycle 1			Cycle 2		
			Week 1	Week 2	Week 3	Week 1	Week 2	Week 3
Patients with relapsed or refractory solid tumors	Cohort 1a Concomitant Schedule	Irinotecan, IV 50 mg/m <sup>2</sup> /day	D1–D5	–	Week off	D1–D5	–	Week off
		Vincristine, IV 1.5 mg/m <sup>2</sup>	D1	D8		D1	D8	
		REG, PO 72 mg/m <sup>2</sup> escalating to 82 mg/m <sup>2</sup> /day (60 mg/m <sup>2</sup> escalating to 65 mg/m <sup>2</sup> /day for patients aged 6 months to <24 months)	D1–D14			D1–D14		
	Cohort 1b Sequential Schedule	Irinotecan, IV 50 mg/m <sup>2</sup> /day	D1–D5	–	–	D1–D5	–	–
		Vincristine, IV 1.5 mg/m <sup>2</sup>	D1	D8	–	D1	D8	–
		REG, PO 72 mg/m <sup>2</sup> escalating to 82 mg/m <sup>2</sup> /day (60 mg/m <sup>2</sup> escalating to 65 mg/m <sup>2</sup> /day for patients aged 6 months to <24 months)	–	D8–D21		–	D8–D21	

D, day; IV, intravenously; PO, orally; REG, regorafenib.